Amryt Pharma signs new distribution deal with Swixx BioPharma
Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Swixx BioPharma of Baar, Switzerland on Monday.
The AIM-traded firm said it had appointed Swixx as exclusive distributor of ‘Lojuxta’, or lomitapide, across 17 jurisdictions in central and eastern Europe.
It said the agreement followed on from its appointment of Swixx in June as the exclusive distributor of ‘Myalepta’, or metreleptin, across the central and eastern Europe territories.
Under the agreement, Swixx would distribute Lojuxta from October in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.
In addition, from January, Swixx would expand its distribution of Lojuxta into the Czech Republic, Hungary and Slovenia.
“Lomitapide is an important contributor to Amryt’s commercial performance and growth and today’s announcement demonstrates the progress we are making in expanding lomitapide’s reach in existing and new territories,” said chief executive officer Joe Wiley.
“This agreement will help bring lomitapide to even more patients in need.
“Also, we are excited to grow and consolidate our existing partnership with Swixx who currently distribute metreleptin exclusively across the central and eastern Europe territories.”
At 0815 BST, shares in Amryt Pharma Holdings were up 2.79% at 200.44p.